Drug shortage
Adalimumab-adaz Injection · Sandoz Inc.
FDA drug shortage · To Be Discontinued · updated Apr 14, 2025
Key facts
| Generic name | Adalimumab-adaz Injection |
|---|---|
| Proprietary name | Hyrimoz |
| Company | Sandoz Inc. |
| Presentation | Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-20) |
| Dosage form | Injection |
| Strength | 80 mg/.8 mL |
| Status | To Be Discontinued |
| Therapeutic category | Rheumatology |
| Package NDCs | 61314-454-20 |
| First posted | Apr 14, 2025 |
| Last updated | Apr 14, 2025 |
| Discontinued | Apr 14, 2025 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: